Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT00238368
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • filgrastim — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • busulfan — DRUG
  • cisplatin — DRUG
  • cyclophosphamide — DRUG
  • cytarabine — DRUG
  • doxorubicin hydrochloride — DRUG
  • etoposide — DRUG
  • methylprednisolone — DRUG
  • prednisone — DRUG
  • vincristine sulfate — DRUG
  • autologous bone marrow transplantation — PROCEDURE
  • peripheral blood stem cell transplantation — PROCEDURE
  • positron emission tomography — PROCEDURE
  • fludeoxyglucose F 18 — RADIATION
  • radiation therapy — RADIATION

Study Details

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy with an autologous stem cell or bone marrow transplant may allow more chemotherapy to be given so that more cancer cells are killed. Procedures, such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) (done during chemotherapy) may help doctors predict a patient's risk of relapse and help plan the best treatment. PURPOSE: This phase II trial is studying how well FDG-PET works in predicting risk of relapse in patients with aggressive non-Hodgkin's lymphoma who are undergoing combination chemotherapy with or without autologous stem cell or bone marrow transplant.

Key Dates

Start date
Feb 29, 2004
Status verified
Nov 2017
Primary completion
Sep 17, 2007
Completion
Sep 17, 2007

Study Design

Enrollment
59 participants (actual)
Primary purpose
DIAGNOSTIC

Primary Outcome Measure

2-year event free survival

Locations (1)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-

Find similar trials in Baltimore, MD

By research site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Related Studies